DRTS
Alpha Tau Medical Ltd.Healthcare·Biotechnology
$10.83
$953M market cap
Revenue
$0.0M
Free Cash Flow
$-32.8M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is he
2-Year Price History
$10.04+311.5%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2025-Q4 | 0.0 | -12.5 | -12.6 | -12.1 | -26.7 | -32.8 | -6.1 | 76.9 | 13.7 | 85.7 | -129.6% | -- | -- |
Valuation & Metrics
Market Stats
Price$10.83
Market Cap$953M
Enterprise Value$890M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-3.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-12.1M
Free Cash Flow$-32.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-129.6%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.0M
Days to Cover3.0
Change (vs Prior)+11.9%
Need at least 2 settlement dates for chart
Employees
Headcount125
Revenue / Employee$0
Gross Profit / Employee$0
Cash Runway
28.2months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
2.9%(+2.6% YoY)
47 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.1%(+0.0% YoY)
3 filers
Vanguard, iShares, SPDR
Market makers
0.1%(+0.1% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| HighTower Advisors, LLC | $6.2M | $3.93 | +$1.3M | +$4.6M | -0.2% | $93.93B |
| Aquamarine Financial (Cayman) Ltd | $5.1M | $7.07 | +$5.1M | +$5.1M | +18.9% | $1.37B |
| Apella Capital, LLC | $3.1M | $4.95 | +$0 | +$3.1M | -0.0% | $6.61B |
| ARK Investment Management LLC | $2.1M | $7.07 | +$2.1M | +$2.1M | -1.7% | $12.86B |
| UBS Group AG | $2.0M | $6.56 | +$1.9M | +$1.8M | -0.3% | $562.11B |
| Kovitz Investment Group Partners, LLC | $1.0M | $2.57 | −$76K | −$560K | -0.4% | $4.31B |
| Daytona Street Capital LLC | $1.0M | $4.95 | −$36K | +$1.0M | -1.7% | $124M |
| Mariner, LLC | $1.0M | $4.42 | +$150K | +$751K | -0.1% | $85.47B |
| Gem Investment Advisors, LLC | $804K | $4.95 | −$227K | +$804K | +5.3% | $102M |
| LEVIN CAPITAL STRATEGIES, L.P. | $752K | $3.22 | −$536K | −$821K | +0.4% | $1.31B |
| JANE STREET GROUP, LLCMM | $534K | $7.07 | +$534K | +$534K | -0.1% | $92.10B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $378K | $6.65 | +$110K | +$110K | +2.3% | $1.61T |
| WELLS FARGO & COMPANY/MN | $349K | $6.04 | +$182K | +$349K | -0.2% | $497.71B |
| Private Advisor Group, LLC | $336K | $3.01 | +$0 | +$0 | -0.1% | $21.04B |
| MILLENNIUM MANAGEMENT LLC | $328K | $4.80 | −$434K | +$328K | -0.5% | $127.40B |
| BANK OF AMERICA CORP /DE/ | $293K | $4.69 | −$19K | +$287K | -0.1% | $1.36T |
| SATOVSKY ASSET MANAGEMENT LLC | $288K | $2.97 | −$91K | −$91K | -0.1% | $566M |
| RENAISSANCE TECHNOLOGIES LLC | $286K | $4.26 | −$152K | +$286K | +1.2% | $63.91B |
| CITADEL ADVISORS LLC | $250K | $2.59 | −$178K | −$173K | -0.4% | $138.22B |
| NORTHERN TRUST CORPPassive | $236K | $3.05 | −$3K | −$83K | -0.2% | $755.34B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+3.37%
avg per quarter
Holders (ex-self)
+3.34%
excl. this stock
Buyers (this Q)
+6.70%
24 buyers · $0.01B in
Sellers (this Q)
+0.18%
18 sellers · $-0.00B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-11.5%
how holders react when this stock falls
On quiet Qs
+5.5%
−10% to +10% baseline
On rallies (+10%+)
-11.7%
how they react when this stock rises
Holders' portfolio flow this Q
+8.0%
inflows — adds are organic
Sellers' portfolio flow this Q
+2.4%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-0.0%
Holder mid (any stock)
+1.2%
Holder rally (any stock)
-3.5%
Biggest decreases this quarter
LEVIN CAPITAL STRATEGIES, L.P.−$536Kα+0.4MILLENNIUM MANAGEMENT LLC−$434Kα-0.5Gem Investment Advisors, LLC−$227Kα+5.3CITADEL ADVISORS LLC−$178Kα-0.4RENAISSANCE TECHNOLOGIES LLC−$152Kα+1.2Summit Financial, LLC−$99Kα+0.0Quent Capital, LLCexited−$99KSATOVSKY ASSET MANAGEMENT LLC−$91Kα-0.1Kovitz Investment Group Partners, LLC−$76Kα-0.4Daytona Street Capital LLC−$36Kα-1.7
New buyers this quarter
Top-5 holders · 63.5%
HighTower Advisors, LLC--
Aquamarine Financial (Cayman) Ltd--
Apella Capital, LLC--
ARK Investment Management LLC--
UBS Group AG--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
HighTower Advisors, LLC875KAquamarine Financial (Cayman) Ltd722KFMR LLC—Apella Capital, LLC382KARK Investment Management LLC292KUBS Group AG287KCITIGROUP INC500Corbin Capital Partners, L.P.—Kovitz Investment Group Partners, LLC147KDaytona Street Capital LLC146K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (3 analysts)$11.67780.0%
Last Year (4 analysts)$11.00160.0%
Current Price$10.83
Analyst Ratings
4
1
Buy: 4Hold: 1Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
29.0%retail-3.2pp
12.6%dark+2.3pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Alpha Tau Medical: Massive Dilution and Related-Party Equity Transfers Mask High Cash Burn
Overall Risk
7/10
Fraud
3/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
5/10
Legal
4/10
Audit Warnings
2/10
Hidden Upside
6/10
Contextually Acceptable
5/10